March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London
March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the unknown causes of preterm birth and new ways to prevent it.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180306006632/en/
This March of Dimes Prematurity Research Center at Imperial College London is supported by a grant from Ferring Pharmaceuticals. Both Ferring and March of Dimes are committed to advancing research to help prevent the 15 million preterm births each year worldwide. Preterm birth is responsible for 1.1 million infant deaths each year.1
“We’re delighted that the talented scientists at Imperial College London will join as the sixth March of Dimes Prematurity Research Center to help us get closer to a world in which all babies are born healthy,” said Stacey D. Stewart, president of March of Dimes. “It’s vital that our team is able to share information and findings with colleagues outside of the U.S., in order to accelerate the discovery of solutions to the serious problem of premature birth.”
“Globally, too many babies are being born too soon, and too many families are suffering the consequences,” said Per Falk, Executive Vice President and Chief Science Officer, Ferring Pharmaceuticals. “Ferring is committed to addressing unmet patient needs in reproductive medicine and women’s health, including the growing rates of preterm birth worldwide. We believe that this new center will accelerate the development of new healthcare solutions that are urgently needed to help babies that are born earlier than expected.”
Phillip Bennett, Professor of Obstetrics and Gynaecology at Imperial College London, and the principal investigator of the new Center, said, “We are proud to have been selected to join the March of Dimes Prematurity Research Center family. Imperial College London and its partner hospitals have renowned clinics for supporting women who deliver preterm, as well as a long tradition of ground-breaking research in this area. As London is a truly global city, we are also fortunate to encompass a large and diverse patient population.”
“Our teams of world-class scientists will be using the latest technologies, some unique to Imperial, to study how the body recognises and interacts with bacteria and other microbes in the birth canal. This will enable us to develop methods for predicting--and ultimately preventing--preterm birth.”
The March of Dimes European Prematurity Research Center at Imperial College London will be a partnership between the College and three major London hospitals: Queen Charlotte’s and Chelsea, St. Mary’s Hospital, and Chelsea and Westminster. Each of these hospitals deliver around 5,000 babies a year.
The network of March of Dimes Prematurity Research Centers encompasses approximately 200 scientists in numerous fields, including obstetrics, neonatology, genetics and genomics, immunology, engineering, informatics, and social sciences. (NOTE: See below for a complete list of the Prematurity Research Centers).
Each March of Dimes Prematurity Research Center is assigned a theme or research target. The theme selected for Imperial College London is entitled, “Microbe-Host Interactions.” This team of scientists will identify and characterise these complex processes in order to obtain insight into why some women are at higher risk for preterm birth.
About Preterm Birth
Preterm birth (before 37 weeks of pregnancy) and its consequences are the leading cause of death among children under age five worldwide. Babies who survive an early birth often face lifelong health challenges, such as breathing problems, cerebral palsy, and learning disabilities. The preterm birth rate is on the rise in the United States, climbing for a second year in a row in 2016.
Quick viewable link for B-roll footage on preterm birth: https://www.youtube.com/watch?v=FbFhPnJy3B0
To download B-roll footage on preterm birth: http://bit.ly/2GUyWMsMOD-Imperial-broll
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.
Imperial is the UK's most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry.
About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every family can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we stand up for every mom and every baby. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.
Because premature birth is such a complex problem, with multiple causes, March of Dimes has chosen Prematurity Research Centers and partners who can use different tools and methods to examine the factors involved in different ways. Each center’s work informs and amplifies the work the other centers are pursuing.
The other five March of Dimes Prematurity Research Centers are located at (with date of launch):
• Stanford University School of Medicine (2011);
• Ohio Collaborative (2013);
• Washington University in St. Louis (2014);
• University of Pennsylvania Perelman School of Medicine (2014);
• University of Chicago-Northwestern University-Duke University (2015).
# # #
1 Born Too Soon: The Global Action Report on Preterm Birth. (WHO, March of Dimes) 2012.
For more information, please contact:
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
Imperial College London
Head of Communications
+44 (0) 207 594 6704
Research Media Officer – Medicine
+44 (0) 207 594 2409
March of Dimes
Director of Media Relations
+ 1 (914) 997 4613
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Elliott Advisors (UK) Limited Statement on Telecom Italia23.3.2018 07:00 | Pressemelding
Given the momentum behind Elliott's campaign at Telecom Italia to improve both performance and governance, Elliott was not surprised to see yesterday's resignation of seven board members affiliated with Vivendi. Unable to advance any meritorious arguments, the Board has simply abandoned their posts to stall for time. Elliott regards this action as cynical and self-serving, in that it delays the ability of Telecom Italia shareholders to express their votes at the upcoming AGM. This is yet another example of minority shareholder rights at Telecom Italia being abrogated and the continued disregard of corporate governance best practice. Finally, Vivendi should note Elliott's forty-year track record of consistent value creation, and sustained, long-term commitments to expose poor governance and catalyse positive change; Elliott's investment history in Telecom Italia dates back to 1999, well before Vivendi became a shareholder in the Company. About Elliott Elliott Management Corporation mana
Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00 | Pressemelding
The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005050/en/ Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements
Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 07:00 | Pressemelding
SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre
Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma23.3.2018 06:00 | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) provided a positive opinion for Cabometyx® (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma (aRCC).The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, Executive Vice President, R&D and Chief Scientific Officer said: “Today’s positive opinion from the CHMP is important news for patients with previously untreated advanced renal cell carcinoma, who can shortly benefit from Cabometyx ® as a new first-line treatment option. Following the evidence of its clinical value after a prior VEGF-targeted treatment, we are pleased to be able to expand the benefit of Cabometyx ® for treatment-naïve patients wit
Swiss Wearable Brand MyKronoz Breaks Worldwide Records with its Hybrid Smartwatch ZeTime, on the Sidelines of a Challenging Baselworld 201822.3.2018 16:32 | Pressemelding
On the sidelines of a downsized Baselworld 2018, MyKronoz, the premier watchmaking brand of the smart generation today announces record-breaking crowdfunding results of its hybrid smartwatch ZeTime, with more than $8,000,000 raised in less than a year. The international success of its unique and groundbreaking flagship wearable is followed by the release of a new digital video campaign “I’m a watch; I’m a smartwatch”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005963/en/ MyKronoz ZeTime Petite & Regular top $8M in crowdfunding (Photo: Business Wire) After a historic 35-days Kickstarter campaign launched in March 2017, ZeTime has pursued, since then, its crowdfunding journey on a variety of international and local platforms: Indiegogo, Makuake in Japan, Zec Zec in Taïwan, Wadiz in Korea and on the leading chinese e-commerce website JD.com. Further to this online momentum, MyKronoz has successfully shipped to over 10
Redwood Software Announces First Industry Robotic Licensing Model to Revolutionize Transparent Marketplace Pricing22.3.2018 14:59 | Pressemelding
Redwood Software, the pioneer behind ‘The Robotic Enterprise’, today announced the launch of a revolutionary new robotic licensing model, where customers only pay for the robotic services they consume within their business. Available now, this new licensing model allows customers to directly compare the costs of manual work against processes that are robotized. With the unique Robotic Service Charge, Redwood only charges for the delivery of a robotic service, equivalent to a unit of work that can done by a person (send an email, download a report, reconcile two reports etc.). Redwood delivers a catalogue of 35,000 of these ready built robotic services that can be linked together by business users in a visual plug and play interface. End-to-end business processes can be modelled, robotized, tested and deployed without cost and risk. Only when the robotic service is consumed is a charge made, always replacing work that would otherwise be done manually. Within the Robotic Service Charge,